2023
IL-18BP mediates the balance between protective and pathological immune responses to Toxoplasma gondii
Clark J, Weizman O, Aldridge D, Shallberg L, Eberhard J, Lanzar Z, Wasche D, Huck J, Zhou T, Ring A, Hunter C. IL-18BP mediates the balance between protective and pathological immune responses to Toxoplasma gondii. Cell Reports 2023, 42: 112147. PMID: 36827187, PMCID: PMC10131179, DOI: 10.1016/j.celrep.2023.112147.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsHumansImmunity, InnateInterleukin-12Interleukin-18Killer Cells, NaturalToxoplasmaToxoplasmosis, AnimalConceptsInnate lymphoid cellsIL-18IL-18BPNatural killerToxoplasma gondiiIL-18 binding proteinEndogenous IL-18Exogenous IL-18Cell-mediated pathologyPathological immune responsesProduction of IFNAnti-pathogen responsesCell productionInterleukin-18Immune pathologyImmune responseLymphoid cellsCell responsesInnate resistanceCD4IFNGondiiInfectionPathologyLimited role
2020
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy
Zhou T, Damsky W, Weizman OE, McGeary MK, Hartmann KP, Rosen CE, Fischer S, Jackson R, Flavell RA, Wang J, Sanmamed MF, Bosenberg MW, Ring AM. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 2020, 583: 609-614. PMID: 32581358, PMCID: PMC7381364, DOI: 10.1038/s41586-020-2422-6.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCD8-Positive T-LymphocytesDisease Models, AnimalFemaleHepatocyte Nuclear Factor 1-alphaHistocompatibility Antigens Class IHumansImmunotherapyIntercellular Signaling Peptides and ProteinsInterleukin-18Kaplan-Meier EstimateKiller Cells, NaturalLymphocytes, Tumor-InfiltratingMaleMiceNeoplasmsReceptors, Interleukin-18Stem CellsTumor MicroenvironmentConceptsIL-18IL-18BPT cellsAnti-PD-1 resistant tumorsWild-type IL-18Potent anti-tumor effectsMajor histocompatibility complex class IIL-18 pathwayIL-18 therapyInterleukin-18 pathwayMajor therapeutic barrierStem-like TCF1Anti-tumor immunityTumor-infiltrating lymphocytesNatural killer cellsRecombinant IL-18Histocompatibility complex class IAnti-tumor effectsComplex class IAnti-tumor activityMouse tumor modelsModern immunotherapyPrecursor CD8Effector CD8Exhausted CD8